The S&P 500 soared more than 32% in 2013, and several big pharma companies, namely Bristol-Myers Squibb (BMY -1.96%), AbbVie (ABBV -0.78%), Roche (RHHBY -2.12%), Johnson & Johnson (JNJ 0.92%), and AstraZeneca (AZN -2.77%) also performed extraordinarily well. The following slideshow reveals why these companies beat out their big pharma peers and what drove their strong performances in 2013.
The pharmaceutical sector had a stellar 2013, but which stocks were the best?
Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences, ImmunoGen, and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Our Most Popular Articles
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.